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Abstract 
Background: Safety of heparin bridging therapy for transrectal ultrasound-guided prostate (TRUS) biopsy in patients 
requiring temporary discontinuation of antithrombotic therapy is unknown. This study aimed to assess the relation-
ship between heparin bridging therapy and the incidence of complications after TRUS biopsy.
Methods: From January 2005 to November 2015, we performed 1307 consecutive TRUS biopsies on 1134 patients 
in our hospital. The patients were assigned to two groups: those without heparin bridging (the control group) and 
those with temporary discontinuation of antithrombotic agents with heparin bridging therapy (the bridging group). 
A 10–12-core TRUS biopsy was performed; the patients were evaluated for bleeding-related complications.
Results: Of 1134 patients, 1109 (1281 biopsies) and 25 (26 biopsies) were assigned to the control and bridging 
group, respectively. Patient background did not significantly differ between the control and bridging groups, except 
for age, history of diabetes, cardiovascular diseases, and CHADS2 scores. Compared with the control group, the bridg-
ing group showed a significantly higher rate of complication for any complication (35 vs. 8.3%, P < 0.001), bleeding-
related complications (27 vs. 4.4%), and urinary tract infection (7.7 vs. 1.2%). No thromboembolic event was observed 
in the present study. Multivariate logistic analysis showed that heparin bridging therapy was a significant risk factor for 
the incidence of any complication and bleeding-related complications.
Conclusions: Heparin bridging therapy with temporal discontinuation of antithrombotic agents may increase the 
risk of complications after TRUS biopsy. Further, large-scale studies are required to clarify the safety of heparin bridging 
therapy.
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Background
An estimated 106,032 transrectal ultrasound-guided 
prostate biopsies (TRUS biopsies) are performed annu-
ally in Japan (Kakehi and Naito 2008). TRUS biopsy is 
the current gold standard for diagnosing prostate cancer 
and is one of the most commonly performed procedures. 
The complications of TRUS biopsy have previously been 
described (Loeb et al. 2013; Nam et al. 2013; Pinkhasov 
et  al. 2012; Rosario et  al. 2012). The most frequent of 
these, which are usually self-limiting, is hematuria (14.7–
81.5%) (Giannarini et al. 2007; Ihezue et al. 2005; Kakehi 
and Naito 2008). Although the majority of patients have 
minor hematuria without complications, a few (0.3–6.2%) 
can develop severe problems (Nam et al. 2013; Pinkhasov 
et al. 2012; Rosario et al. 2012).
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As the world’s population ages rapidly, a relatively 
high proportion of patients are on prescribed medica-
tion for comorbidities; these medications include long-
term antithrombotic therapy using low-dose aspirin, 
clopidogrel/ticlopidine, and warfarin. Several prospec-
tive studies support the safety of continuation of low-
dose aspirin in TRUS biopsy (Giannarini et  al. 2007; 
Maan et al. 2003). Conversely, no recommendation exists 
regarding the management of non-aspirin antithrom-
botic agents (warfarin or clopidogrel/ticlopidine) before 
a TRUS biopsy. Clinicians have three options for man-
agement, depending on the risk of thrombosis. First, 
antithrombotic agents can be continued during proce-
dures associated with low rates of bleeding complica-
tions. Second, they can be discontinued for several days 
prior to the procedure and restarted thereafter. Third, 
they can be discontinued with bridging anticoagulation 
using heparin (heparin bridging therapy), administered 
during the sub-therapeutic window, in patients at high 
risk of thromboembolic events (Douketis et  al. 2008; 
El-Hakim and Moussa 2010). However, there are few 
prospective studies regarding the relationship between 
TRUS biopsy and continuation of antithrombotic agents. 
Furthermore, the safety of short-term discontinuation of 
antithrombotic agents with heparin bridging therapy in 
TRUS biopsy has not been well documented. Therefore, 
we aimed to assess the safety of heparin bridging therapy 
for TRUS biopsy in patients requiring temporary discon-
tinuation of antithrombotic agents in the present study.
Methods
Patient selection and evaluation
From January 2005 to November 2015, we performed 
1307 TRUS-biopsies on 1134 patients in our hospital. 
We retrospectively investigated the relationship between 
heparin bridging therapy and the incidence of complica-
tions after TRUS biopsy and evaluated the prevalence 
of these complications in patients not receiving heparin 
bridging therapy. Patients were assigned to two groups: 
those without heparin bridging (the control group, 
n = 1109; 1281 biopsies) and those with temporary dis-
continuation of antithrombotic agents with heparin 
bridging therapy (the bridging group, n  =  25; 26 biop-
sies). The control group included patients not adminis-
tered any antithrombotic agents or those with temporary 
discontinuation of antithrombotic agents. Clinical indi-
cation of heparin bridging therapy was assessed by 
the physician who had medicated the patient with 
antithrombotic agents, according to the individual risks 
of thromboembolism. A 10- to 12-core TRUS biopsy was 
performed, and patients were surveyed to evaluate any 
complications and bleeding-related events. The incidence 
of complications and grades for each group was assessed 
by reference of medical charts, according to the Common 
Terminology Criteria for Adverse Events (version 4.0). 
Multivariate logistic regression analysis was performed 
to assess the risk factors for the incidence of complica-
tions (of any grade), including age, heparin bridging, 
presence of comorbidities (diabetes mellitus and hyper-
tension), number of biopsy cores, and the CHADS2 score 
(congestive heart failure: 1 point; hypertension: 1 point; 
age 75 or older: 1 point; diabetes mellitus: 1 point; prior 
stroke or transient ischemic attack or thromboembolism: 
2 points). The CHADS2 score is a clinical prediction rule 
for estimating the risk of stroke in patients with non-
rheumatic atrial fibrillation that is a common and serious 
heart arrhythmia associated with thromboembolic stroke 
(Gage et al. 2001). To evaluate the accuracy and reliability 
of the CHADS2 score in clinical practice, we compared 
the international normalized ratio of prothrombin time 
(PT-INR) and CHADS2 score between heparin bridging 
and non-bridging heparin-administered patients.
Statistical analysis
Statistical analyses of the clinical data were performed 
using SPSS version 22.0 (SPSS Inc., Chicago, IL, USA) 
and GraphPad Prism 5.03 (GraphPad Software, San 
Diego, CA, USA). Categorical variables were reported 
as percentages and compared using the Fisher’s exact 
test. Quantitative data were expressed as medians with 
quartiles 1 and 3 (Q1 and Q3). Differences between the 
groups were statistically compared using the Student’s t 
test for normal distribution or the Mann–Whitney U-test 
for non-parametric distribution. P values <0.05 were 
considered statistically significant. Risk factors for any 
complications and bleeding-related events were identi-
fied using univariate and logistic regression multivariate 
analyses. Odds ratios (ORs) with 95% confidence inter-
vals were calculated after concurrently controlling for 
potential confounders. Variables included in the models 
were age (>70 years), history of type 2 diabetes (positive), 
history of hypertension (positive), prostate-specific anti-
gen (>7.8 ng/mL), prostate cancer (positive), the number 
of biopsy cores (>10), use of antithrombotic agents (posi-
tive), the number of antithrombotic agents (2 or more), 
use of warfarin (positive), heparin bridging (positive), 
and the CHADS2 score (2 or higher). The median was 
used as a cut-off value in quantitative data.
Ethics statement
This study was performed in accordance with the ethical 
standards of the Declaration of Helsinki and approved 
by the ethics review board of Hirosaki University School 
of Medicine (Authorization Number: 2013-315). For 
this type of retrospective study, formal consent was not 
required.
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Results
Of 1134 patients, 1109 (1281 biopsies) and 25 (26 biop-
sies) were assigned to the control and bridging groups, 
respectively. The control group was consisted of the 
patients without any antithrombotic agents (1013 biop-
sies) and those with temporary discontinuation of 
antithrombotic agents (268 biopsies). The rates of any 
complications and bleeding-related complications in 
without any antithrombotic agents and those with tem-
porary discontinuation of antithrombotic agents were 7.7 
and 10% (P =  0.314), 4.5 and 3.7% (P =  0.737), respec-
tively. Because no significant differences were observed 
in complication rates between the groups, we integrated 
those patients in control group.
In the bridging group, the number of patients with 
oral antithrombotic agents were as follows; warfarin 13, 
low-dose aspirin 3, clopidogrel 1, dabigatran 1, warfa-
rin +  low-dose aspirin 3, low-dose aspirin +  ticlopidine 
2, warfarin + low-dose aspirin + ticlopidine 2, and war-
farin + low-dose aspirin + cilostazol + sarpogrelate 1.
There were no significant differences in patient back-
grounds between the groups, except for age, history of 
diabetes, use of antithrombotic argents, cardiovascular 
diseases, and CHADS2 scores (Table 1). Compared with 
the control group, the patients in the heparin bridging 
group were significantly older (70 vs. 74  years), had a 
higher prevalence of diabetes (11 vs. 27%), and a higher 
CHADS2 score (0 vs. 2 points). The total number of 
complications and the bleeding-related events were 106 
(8.3%) and 57 (4.4%) cases in the control group and 9 
(35%) and 7 (27%) cases in the bridging group, respec-
tively. The incidence of complications in the bridging 
group was significantly higher than that in the control 
group. However, no significant difference was observed 
for severe (grade 3 or higher) complications. No throm-
boembolism-associated complication was observed in 
the present study (Table 1). Multivariate logistic analysis 
showed that diabetes, numbers of biopsy cores >10, and 
heparin bridging were selected as risk factors for the inci-
dence of any complications (Table 2). In bleeding-related 
events, age >70 and heparin bridging were significant risk 
factors. Use of non-aspirin antithrombotic agents was 
not statistically significant for bleeding-related complica-
tions (Table 2).
Our study included 68 patients who were taking war-
farin before TRUS biopsy. Of these, 19 and 49 patients 
were assigned to warfarin discontinuation with and with-
out heparin bridging (discontinuation alone) groups by 
the primary physician, respectively. We compared the 
PT-INR and CHADS2 scores between these two groups. 
Our data showed that PT-INR was significantly higher in 
heparin bridging patients. However, CHADS2 score was 
not significantly different between the groups (Table 3).
To assess the safety of heparin bridging therapy, we 
compared patients with temporary discontinuation of 
antithrombotic agents (n = 268) and the bridging group 
(n  =  26). Although there were age differences between 
the groups, the rates of any complications and bleeding-
related complications in those with discontinuation and 
the bridging group are 9.7 and 35% (P = 0.001), 3.7 and 
27% (P = 0.001), respectively (Table 4).
Discussion
The potential risk of severe hemorrhage requiring hospi-
talization was reportedly 1/500 in men undergoing TRUS 
biopsy without warfarin administration, with a theo-
retical fivefold increase in men administered warfarin 
as an anticoagulant (Ramachandran et al. 2005). When a 
patient is considered to be at a low or intermediate risk 
for thromboembolism, most clinicians advocate discon-
tinuation of antithrombotic therapy prior to TRUS biopsy 
and recommend continuation only after any bleeding has 
stopped (Cochlin 2005). The risk of thrombotic events 
associated with stopping warfarin is reportedly approxi-
mately 1% (Wahl 1998; Yasaka et al. 2001). Several obser-
vational studies have suggested that simply interrupting 
warfarin therapy for <7 days is associated with a very low 
rate of thromboembolism and severe bleeding complica-
tions (Garcia et al. 2008; Wysokinski et al. 2008). A sur-
vey among urologists and radiologists found that 84% of 
urologists stopped warfarin 4  days before TRUS biopsy, 
and 95% of radiologists stopped it 5  days before TRUS 
biopsy (Connor and Wingate 1999). A PT-INR of less 
than 1.5 is accepted for most elective procedures (Kearon 
and Hirsh 1997).
When patients have a high risk of thromboembo-
lism, either continuation of antithrombotic agents or 
discontinuation of antithrombotic agents with heparin 
bridging therapy is required. As a definitive recommen-
dation regarding the management of antithrombotic 
agents before TRUS biopsy is yet to be established, the 
benefits and adverse effects of heparin bridging ther-
apy are debatable. Clinicians have traditionally dis-
continued antithrombotic agents and started heparin 
bridging therapy, depending on the risk of thrombotic 
events (Douketis et  al. 2008; El-Hakim and Moussa 
2010). The guidelines for the management of antithrom-
botic agents for endoscopic procedures suggest heparin 
bridging therapy for higher-risk procedures (e.g., pol-
ypectomy) in high-risk patients (e.g., those with atrial 
fibrillation with mechanical valves, valvular heart disease, 
and/or a history of cerebrovascular accidents, and those 
who experience transient ischemic attacks) (Murasaki 
2011). A recent prospective study suggested that hepa-
rin bridging therapy increased the risk of bleeding com-
plications from interruption alone (0.8%) to bridging 
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(13%) in colonoscopy and oral and ophthalmic surgeries 
(Garcia et  al. 2008). However, there is little reliable evi-
dence for the benefits and harm associated with heparin 
bridging therapy in TRUS biopsy. To our knowledge, this 
is the first report to describe the risk of heparin bridg-
ing therapy for TRUS biopsy in patients requiring tempo-
rary discontinuation of antithrombotic agents. Our data 
suggested that discontinuation of antithrombotic agents 
with heparin bridging therapy increased the incidence of 
complications after TRUS biopsy. Furthermore, there was 
an increase in bleeding-related complications and urinary 
tract infections. Although the majority of complication 
grades were low (1 or 2), the incidence rate of complica-
tions was significantly higher in heparin bridging patients 
than in control patients. Similarly to a previous study 
(Garcia et al. 2008), our results suggested the possibility 
that heparin bridging therapy may cause more harm than 
good. From a different perspective, this is reasonable 
because patients who are indicated for heparin bridging 
therapy have a number of severe comorbidities. In fact, 
our patients treated with heparin bridging therapy had a 
significantly higher prevalence of diabetes and cardiovas-
cular diseases. Therefore, it is possible that those patients 
who were recommended heparin bridging therapy have a 
high risk for complications, and careful management of 
such complications is required in these patients.
In addition, the patients with temporary discontinu-
ation of antithrombotic agents should be compared to 
the bridging group to assess the safety of heparin bridg-
ing therapy. The rates of any complications and bleed-
ing-related complications in those with discontinuation 
and the bridging group were 9.7 and 35% (P  =  0.001), 
3.7 and 27% (P = 0.001), respectively. This result implies 
that the heparin bridging itself, in spite of the past use of 
Table 1 Patient background, and incidents and rates of complications
Median and interquartile range (Q1, Q3) was used for consecutive variables
PT-INR prothrombin time-international normalized ratio, NOAC novel oral anticoagulant
All Control Bridging P value
Biopsy, n 1307 1281 26
Patients, n 1134 1109 25
Age (years) 70 (65, 74) 70 (65, 70) 74 (71, 76) <0.001
PSA (ng/mL) 7.8 (5.4, 13.5) 7.8 (5.4, 13.5) 10.5 (6.8, 14.6) 0.099
Diabetes, n 131 (13%) 124 (11%) 7 (27%) 0.011
Hypertension, n 423 (32%) 411 (37%) 12 (46%) 0.141
Frequencies of biopsy 1 (1, 2) 1 (1, 2) 1 (1, 1) 0.970
Number of cores 10 (10, 12) 10 (10, 12) 10 (10, 10) 0.523
Prostate cancer, n 607 (46%) 594 (46%) 13 (50%) 0.843
Use of any antithrombotic agents (any), n 294 (23%) 268 (21%) 26 (100%) <0.001
 Low dose aspirin 191 (15%) 11 (42%)
 Warfarin 52 (4.1%) 19 (73%)
 Clopidogel/ticlodipine 37 (2.9%) 7 (27%)
 NOAC 3 (0.2%) 1 (3.8%)
Reason for antithrombotic agents use, n
 Atrial fibrillation (Af ) 157 (12%) 139 (11%) 18 (69%)
 Myocardial infarction (MI) 52 (4.0%) 46 (3.6%) 6 (23%)
 Others 86 (6.6%) 84 (6.6%) 2 (8%)
CHADS2 score 0 (0, 0) 0 (0, 1) 2 (0, 2) <0.001
Complications
All events, n 118 (9.0%) 106 (8.3%) 9 (35%) <0.001
 Grade 1 or 2 106 (8.1%) 95 (7.4%) 8 (31%)
 Grade 3 12 (0.9%) 11 (0.9%) 1 (3.8%)
Bleeding related events, n 64 (4.9%) 57 (4.4%) 7 (27%) <0.001
 Grade 1 or 2 57 (4.4%) 51 (4.0%) 6 (23%)
 Grade 3 7 (0.5%) 6 (0.5%) 1 (3.8%)
Urinary tract infection, n 17 (1.3%) 15 (1.2%) 2 (7.7%) 0.043
Others, n 34 (2.6%) 34 (2.7%) 0 (0%) 1.000
Thrombotic events, n 0 (0%) 0 (0%) 0 (0%)
Page 5 of 8Hamano et al. SpringerPlus  (2016) 5:1917 
antithrombotic agents, affects the complication rate. Fur-
thermore, the patient background of these two groups is 
compared to consider the influence of heparin bridging. 
The comorbidity rates of diabetes and hypertension in 
those with discontinuation and the bridging group were 
15 and 27% (P  =  0.160), and 49 and 46% (P  =  0.839), 
respectively. This similarity of background also supports 
the significance of heparin bridging for complication 
rates.
We observed no thrombotic event in this cohort. Our 
results may be biased by the limitations of sample size 
and/or the ethnic differences. The risk of thrombotic 
disease is different between Japanese and Caucasians 
(Murasaki 2011). Therefore, we could not establish the 
benefits or adverse effects of heparin bridging therapy in 
this present study.
To balance the potential benefits and adverse effects, 
continuation of antithrombotic agents is another option 
for reducing thrombotic events. Several studies have 
suggested the safety of continuation of warfarin amid 
TRUS- biopsy. In the studies of Ihezue et al. (2005) and 
Chowdhury et al. (2012), no significant differences were 
observed in the severity of bleeding between the patients 
taking warfarin (36.7 and 27.9%, respectively) and the 
controls (60.2 and 37.0%, respectively). These results 
suggest that discontinuation of warfarin before TRUS 
biopsy is unnecessary. However, the limitations of these 
studies include the non-randomized design, potentially 
life-threatening hemorrhagic complications that may 
have been avoided only due to the sample size and lim-
ited information regarding the proper control of PT-INR. 
Another alternative is a switch of novel oral anticoagu-
lant (NOAC). It may decrease the risk of bleeding and 
thromboembolism (Douketis et al. 2014). However, there 
Table 2 Uni- and multivariate logistic analysis of risk factors for complications
Risk factors Any complications Bleeding-related events
P value HR 95% CI P value HR 95% CI
Univariate
Age >70 years 0.023 1.57 1.06–2.32 0.004 2.14 1.27–3.61
Diabetes Positive 0.004 2.09 1.26–3.44 0.052 1.91 0.99–3.67
Hypertension Positive 0.883 1.03 0.69–1.53 0.802 0.94 0.55–1.58
PSA >7.8 ng/mL 0.641 0.91 0.62–1.34 0.454 0.82 0.50–1.37
Prostate cancer Positive 0.641 0.92 0.63–1.33 0.859 0.96 0.59–1.55
Number of biopsy cores >10 cores 0.063 1.48 0.98–2.23 0.521 1.20 0.69–2.08
Use of oral antithrombotic agents Positive 0.025 1.62 1.06–2.47 0.425 1.26 0.71–2.23
Number of oral antithrombotic agents 2 or more 0.043 1.38 1.01–1.90 0.281 1.26 0.83–1.92
Use of warfarin Positive 0.679 1.19 0.53–2.65 0.745 1.19 0.42–3.37
Heparin-bridging Positive 0.000 5.99 2.61–13.8 0.000 7.91 3.20–19.6
CHADS2 score 2 or higher 0.005 2.30 1.29–4.08 0.003 2.83 1.42–5.61
Multivariate
Age >70 years 0.108 1.39 0.93–2.09 0.015 1.96 1.14–3.36
Diabetes Positive 0.023 1.99 1.10–3.59 0.243 1.60 0.73–3.52
Number of biopsy cores >10 cores 0.025 1.62 1.06–2.47 0.371 1.29 0.74–2.27
Use of oral antithrombotic agents Positive 0.473 1.19 0.74–1.92 0.280 0.68 0.33–1.38
Heparin-bridging Positive 0.002 4.78 1.77–13.0 0.001 7.52 2.29–24.8
CHADS2 score 2 or higher 0.912 0.96 0.44–2.06 0.655 1.25 0.47–3.31
Table 3 Background of patient who are taking warfarin
Median and interquartile range (Q1, Q3) was used for consecutive variables. 
PT-INR: prothrombin time-international normalized ratio
Discontinuation of warfarin P value
Without bridging With bridging
Biopsy, n 49 19
Patients, n 46 18
Age (years) 72 (68, 76) 73 (71, 76) 0.406
PSA (ng/mL) 8.8 (5.4, 13.6) 10.5 (7.0, 14.9) 0.333
Diabetes, n 5 (10%) 5 (26%) 0.128




 Warfarin alone, n 34 (69%) 13 (68%)
 Warfarin + others, n 15 (31%) 6 (32%)
PT-INR (at a target level) 1.55 (1.19, 1.92) 1.89 (1.67, 2.32) 0.026
CHAD2 score 1 (1, 3) 1 (0, 3) 0.701
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is limited evidence for invasive procedures with interrup-
tion of NOAC administration. Further studies are needed 
to evaluate the benefits and adverse effects of discontinu-
ation alone, continuation, or discontinuation with admin-
istration of heparin bridging therapy in TRUS biopsy.
To carefully assess the benefits and adverse effects, risk 
classification is necessary. One of the major risk classifi-
cations is the CHADS2 score (Gage et al. 2004). It is used 
to determine whether or not antithrombotic treatment 
is required. The CHADS2 score is simple and its appli-
cability has been validated by many studies. Based on the 
CHADS2 score, this decision pertaining to the treatment 
modality should be discussed with the patient and the 
primary physician managing the antithrombotic agents. 
To assess the accuracy and reliability of CHADS2 scores 
in clinical practice, we selected 68 patients who were 
taking warfarin and compared the PT-INR and CHADS2 
scores between patients with and without heparin bridg-
ing therapy. Our data showed that the target level of PT-
INR was significantly higher in patients with heparin 
bridging therapy. However, no relationship was observed 
between the CHADS2 score and a recommendation for 
heparin bridging therapy. This finding suggests the dif-
ficulty in truly defining risk stratification and decision 
making, and highlights the urgent need for large-scale 
randomized clinical trials to evaluate the management of 
continuation of antithrombotic agents or bridging ther-
apy in patients undergoing TRUS biopsy.
The present study has several limitations, including 
small sample size, its retrospective nature, and the indi-
cation of heparin bridging therapy. Among these, the 
retrospective design may result in remarkable biases in 
Table 4 Comparison between patients with temporary discontinuation of antithrombotic agents and the bridging group
Median and interquartile range (Q1, Q3) was used for consecutive variables
NOAC novel oral anticoagulant
Temporary discontinuation  
of antithrombotic agents
Bridging P value
Biopsy, n 268 26
Patients, n 235 25
Age (years) 72 (68, 75) 74 (71, 76) 0.016
PSA (ng/mL) 7.6 (5.3, 13.4) 10.5 (6.8, 14.6) 0.329
Diabetes, n 41 (15%) 7 (27%) 0.160
Hypertension, n 132 (49%) 12 (46%) 0.839
Frequencies of biopsy 1 (1, 1) 1 (1, 1) 0.124
Number of cores 10 (10, 10) 10 (10, 10) 0.526
Prostate cancer, n 131(49%) 13 (50%) 0.913
Use of any antithrombotic agents (any), n 268 (100%) 26 (100%)
 Low dose aspirin 191 (15%) 11 (42%)
 Warfarin 52 (4.1%) 19 (73%)
 Clopidogel/ticlodipine 37 (2.9%) 7 (27%)
 NOAC 3 (0.2%) 1 (3.8%)
Reason for antithrombotic agents use, n <0.001
 Atrial fibrillation (Af ) 139 (52%) 18 (69%)
 Myocardial Infarction (MI) 46 (17%) 6 (23%)
 Others 84 (31%) 2 (8%)
CHADS2 score 0 (0, 1) 2 (0, 2) <0.001
Complications
All events, n 26 (9.7%) 9 (35%) 0.001
 Grade 1 or 2 22 (8.2%) 8 (31%)
 Grade 3 4 (1.5%) 1 (3.8%)
Bleeding related events, n 10 (3.7%) 7 (27%) <0.001
 Grade 1 or 2 8 (2.9%) 6 (23%)
 Grade 3 2 (0.7%) 1 (3.8%)
Urinary tract infection, n 4 (1.5%) 2 (7.7%) 0.002
Others, n 12 (4.5%) 0 (0%) 1.000
Thrombotic events, n 0 (0%) 0 (0%)
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this study. For instance, propensity score matching was 
not applied because of the small sample size. On the 
other hand, because the judgement regarding antithrom-
botic therapy possibly causes fatal complications such as 
intracranial hemorrhage and pulmonary embolism, the 
prospective study needs to be designed very carefully in 
the future. Although our study suggested that heparin 
bridging therapy may increase the risk of bleeding com-
plications, safety of this therapy remains inconclusive. 
Despite these limitations, this study is the first to report 
the safety of heparin bridging therapy for TRUS biopsy 
in patients requiring temporary discontinuation of 
antithrombotic agents (Additional file 1).
Conclusion
In conclusion, bridging of temporal discontinuation of 
antithrombotic agents with heparin may increase the 
risk of complications. However, the limited number of 
patients with heparin bridging therapy obfuscates a clear 
interpretation of the results. Further large-scale studies 
are necessary to clarify the benefits and adverse effects of 
heparin bridging therapy.
Abbreviations
TRUS biopsy: transrectal ultrasound-guided prostate biopsy; ASA: acetylsali-
cylic acid; AEs: adverse events; PT-INR: prothrombin time-international normal-
ized ratio; NOAC: non-vitamin K antagonist oral anticoagulation.
Authors’ contributions
IH; collection of data, analyzed of data, writing of the main article. SH; analyzed 
the data, writing of the main article. TY, YT, OS, TM, HY, AI, TY, YH; collection 
of data. TK; intellectual contribution to the manuscript. SH, CO; designed the 
plan of the study. All authors read and approved the final manuscript.
Author details
1 Department of Urology, Hirosaki University Graduate School of Medicine, 
5 Zaifu-cho, Hirosaki 036-8562, Japan. 2 Department of Advanced Transplant 
and Regenerative Medicine, Hirosaki University Graduate School of Medicine, 
Hirosaki, Japan. 
Acknowledgements
The authors thank Dr. Yuki Fujita for the invaluable help with scientific 
suggestions.
Competing interests
The authors declare that they have no competing interests, and no financial 
conflict of interests.
Ethics approval and consent to participate
This study was performed in accordance with the ethical standards of the 
Declaration of Helsinki and approved by the ethics review board of Hirosaki 
University School of Medicine (Authorization Number: 2013-315). For this type 
of retrospective study, formal consent was not required.
Additional file
Additional file 1. Patient background and adverse events of all 1307 
prostate biopsies.
Funding
This work was supported by Grants-in-Aid for Scientific Research No. 23791737 
from the Japan Society for the Promotion of Science.
Received: 15 March 2016   Accepted: 27 October 2016
References
Chowdhury R, Abbas A, Idriz S, Hoy A, Rutherford EE, Smart JM (2012) Should 
warfarin or aspirin be stopped prior to prostate biopsy? An analysis of 
bleeding complications related to increasing sample number regimes. 
Clin Radiol 67:e64–e70. doi:10.1016/j.crad.2012.08.005
Cochlin DL (2005) Biopsy of the prostate guided by transrectal ultrasound: 
relation between warfarin use and bleeding complications. Clin Radiol 
60:457–458
Connor SE, Wingate JP (1999) Management of patients treated with aspirin or 
warfarin and evaluation of haemostasis prior to prostatic biopsy: a survey 
of current practice amongst radiologists and urologists. Clin Radiol 
54:598–603
Douketis JD, Berger PB, Dunn AS, Jaffer AK, Spyropoulos AC, Becker RC, Ansell 
J (2008) The perioperative management of antithrombotic therapy: 
American College of Chest Physicians Evidence-Based Clinical Practice 
Guidelines (8th edition). Chest 133:299S–339S. doi:10.1378/chest.08-0675
Douketis J, Bell AD, Eikelboom J, Liew A (2014) Approach to the new oral 
anticoagulants in family practice: part 2: addressing frequently asked 
questions. Can Fam Physician 60:997–1001
El-Hakim A, Moussa S (2010) CUA guidelines on prostate biopsy methodology. 
Can Urol Assoc J 4:89–94
Gage BF, Waterman AD, Shannon W, Boechler M, Rich MW, Radford MJ 
(2001) Validation of clinical classification schemes for predicting stroke: 
results from the National Registry of Atrial Fibrillation. J Am Med Assoc 
285:2864–2870
Gage BF, van Walraven C, Pearce L, Hart RG, Koudstaal PJ, Boode BS, Petersen P 
(2004) Selecting patients with atrial fibrillation for anticoagulation: stroke 
risk stratification in patients taking aspirin. Circulation 110:2287–2292. 
doi:10.1161/01.cir.0000145172.55640.93
Garcia DA, Regan S, Henault LE, Upadhyay A, Baker J, Othman M, Hylek 
EM (2008) Risk of thromboembolism with short-term interrup-
tion of warfarin therapy. Arch Intern Med 168:63–69. doi:10.1001/
archinternmed.2007.23
Giannarini G et al (2007) Continuing or discontinuing low-dose aspirin before 
transrectal prostate biopsy: results of a prospective randomized trial. 
Urology 70:501–505. doi:10.1016/j.urology.2007.04.016
Ihezue CU, Smart J, Dewbury KC, Mehta R, Burgess L (2005) Biopsy of the pros-
tate guided by transrectal ultrasound: relation between warfarin use and 
incidence of bleeding complications. Clin Radiol 60:459–463; discussion 
457–458. doi:10.1016/j.crad.2004.10.014
Kakehi Y, Naito S (2008) Complication rates of ultrasound-guided pros-
tate biopsy: a nation-wide survey in Japan. Int J Urol 15:319–321. 
doi:10.1111/j.1442-2042.2008.02048.x
Kearon C, Hirsh J (1997) Management of anticoagulation before and 
after elective surgery. New Engl J Med 336:1506–1511. doi:10.1056/
nejm199705223362107
Loeb S et al (2013) Systematic review of complications of prostate biopsy. Eur 
Urol 64:876–892. doi:10.1016/j.eururo.2013.05.049
Maan Z, Cutting CW, Patel U, Kerry S, Pietrzak P, Perry MJ, Kirby RS (2003) Mor-
bidity of transrectal ultrasonography-guided prostate biopsies in patients 
after the continued use of low-dose aspirin. BJU Int 91:798–800
Murasaki K (2011) Guidelines for management of anticoagulant and antiplate-
let therapy in cardiovascular disease (JCS 2009). Nihon Rinsho Jpn J Clin 
Med 69(Suppl 9):567–571
Pinkhasov GI et al (2012) Complications following prostate needle biopsy 
requiring hospital admission or emergency department visits—
experience from 1000 consecutive cases. BJU Int 110:369–374. 
doi:10.1111/j.1464-410X.2011.10926.x
Page 8 of 8Hamano et al. SpringerPlus  (2016) 5:1917 
Nam RK et al (2013) Increasing hospital admission rates for urological com-
plications after transrectal ultrasound guided prostate biopsy. J Urol 
189:S12–S17; discussion S17–S18. doi:10.1016/j.juro.2012.11.015
Ramachandran N, MacKinnon A, Allen C, Dundas D, Patel U (2005) Biopsy of 
the prostate guided by transrectal ultrasound: relation between warfarin 
use and incidence of bleeding complications. Clin Radiol 60:1130. 
doi:10.1016/j.crad.2005.04.017
Rosario DJ et al (2012) Short term outcomes of prostate biopsy in men tested 
for cancer by prostate specific antigen: prospective evaluation within 
ProtecT study. BMJ 344:d7894. doi:10.1136/bmj.d7894
Wahl MJ (1998) Dental surgery in anticoagulated patients. Arch Intern Med 
158:1610–1616
Wysokinski WE, McBane RD, Daniels PR, Litin SC, Hodge DO, Dowling 
NF, Heit JA (2008) Periprocedural anticoagulation management of 
patients with nonvalvular atrial fibrillation. Mayo Clin Proc 83:639–645. 
doi:10.4065/83.6.639
Yasaka M, Minematsu K, Yamaguchi T (2001) Optimal intensity of international 
normalized ratio in warfarin therapy for secondary prevention of stroke in 
patients with non-valvular atrial fibrillation. Int Med 40:1183–1188
